Rocket Pharmaceuticals Inc Market Cap ($286.51 Million)
Market Cap & Net Worth: Rocket Pharmaceuticals Inc (RCKT)
Rocket Pharmaceuticals Inc market cap. Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has a market capitalization of $286.51 Million ($286.51 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14788 globally and #3532 in its home market, demonstrating a 6.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rocket Pharmaceuticals Inc's stock price $2.61 by its total outstanding shares 109774597 (109.77 Million). Also see Rocket Pharmaceuticals Inc (RCKT) cash conversion ratio for how efficiently the company converts equity into cash flow.
Rocket Pharmaceuticals Inc Market Cap History (2015–2026)
Rocket Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $4.97 Billion to $286.51 Million (-22.67% CAGR). Check Rocket Pharmaceuticals Inc share price for real-time trading data and today's change.
Index Memberships
Rocket Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #394 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1438 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.02% | #205 of 263 |
Weight: Rocket Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rocket Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rocket Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RCKT year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RCKT by Market Capitalization
Companies near Rocket Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Rocket Pharmaceuticals Inc for a full breakdown of the balance sheet.
Key companies related to Rocket Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Rocket Pharmaceuticals Inc (2015–2026)
Market capitalization of Rocket Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Rocket Pharmaceuticals Inc's market cap moved from $4.97 Billion to $ 286.51 Million, with a yearly change of -22.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $286.51 Million | -25.64% |
| 2025 | $385.31 Million | -72.08% |
| 2024 | $1.38 Billion | -58.06% |
| 2023 | $3.29 Billion | +53.14% |
| 2022 | $2.15 Billion | -10.35% |
| 2021 | $2.40 Billion | -60.19% |
| 2020 | $6.02 Billion | +140.95% |
| 2019 | $2.50 Billion | +53.58% |
| 2018 | $1.63 Billion | +41.95% |
| 2017 | $1.15 Billion | -57.21% |
| 2016 | $2.68 Billion | -46.16% |
| 2015 | $4.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Rocket Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $286.51 Million USD |
| MoneyControl | $286.51 Million USD |
| MarketWatch | $286.51 Million USD |
| marketcap.company | $286.51 Million USD |
| Reuters | $286.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading … Read more